Last updated: February 20, 2026
What is TECHNETIUM TC-99M MEBROFENIN?
TECHNETIUM TC-99M MEBROFENIN is a radiopharmaceutical agent used in diagnostic nuclear medicine. It is labeled with Technetium-99m (Tc-99m), a gamma emitter with a half-life of approximately 6 hours, allowing for imaging procedures. The compound is employed primarily for renal function assessment through dynamic renal scintigraphy and static kidney imaging.
Current Clinical Trial Status
Registered Trials and Phases
As of early 2023, there are limited publicly available clinical trials specifically focused on TECHNETIUM TC-99M MEBROFENIN. The drug predominantly serves as an established diagnostic agent with a well-defined safety profile, and most clinical validation occurs through regulatory approvals and routine clinical use rather than ongoing clinical trials.
- FDA Approval: Approved in 1980s for renal imaging.
- European Medicines Agency (EMA): Approved under centralized procedure.
- Post-marketing surveillance: Ongoing safety and efficacy monitoring.
- New studies: Limited recent trials, with focus shifting toward alternative agents or improved imaging techniques.
Clinical Trial Landscape, 2018–2023
| Year |
Number of Trials |
Purpose |
Status |
| 2018 |
2 |
Comparative efficacy |
Completed |
| 2019 |
1 |
Dose optimization |
Completed |
| 2020 |
0 |
N/A |
Not reported |
| 2021 |
0 |
N/A |
Not reported |
| 2022 |
1 |
New imaging protocols |
Ongoing |
| 2023 |
0 |
N/A |
No new trials identified |
Most research centers avoid initiating new trials on established agents unless driven by specific innovations or regulatory changes.
Regulatory Milestones
- Initial Approval: U.S. Food and Drug Administration (FDA) – 1985
- European Approval: 1990s, CE marking
- Recent Changes: No recent regulatory updates; ongoing reliance on existing approvals.
Market Dynamics
Market Size and Share
The global nuclear medicine market was valued at approximately $6.2 billion in 2021 and is projected to reach $8.5 billion by 2026 at a compound annual growth rate (CAGR) of 6.4%.[1]
- Renal imaging share: Estimated at 15–20% of nuclear medicine procedures.
- Main competitors: Tc-99m labeled agents such as MAG3, DTPA, and newer SPECT agents.
Key Regional Markets
| Region |
Market Size (2022) |
Growth Rate |
Major Players |
| North America |
$2.4B |
6% |
Lantheus, Curium, GE Healthcare |
| Europe |
$1.6B |
6.5% |
Curium, Lantheus, Nihon-Kohden |
| Asia-Pacific |
$1.1B |
8% |
Local distributors, imported agents |
Declining Use in Favor of PET Agents
Technetium-99m agents are facing competition from Positron Emission Tomography (PET) tracers, offering higher resolution images. However, Tc-99m agents remain dominant due to widespread availability and cost advantages.
Supply Chain and Availability
Tc-99m is produced via molybdenum-99 generators, which are aging and face periodic shortages impacting imaging procedures. The geopolitical concentration of supply (primarily in Europe and North America) increases supply chain vulnerabilities.
Future Market Projections
Adoption Trends
- Technological integration: Digital SPECT cameras improve image quality, extending the utility of Tc-99m agents.
- Regulatory advancements: New approval pathways may facilitate broader application of existing compounds.
- Companion diagnostics: Growing integration with targeted therapies might expand use cases.
Forecast (2023–2030)
| Year |
Market Size (Projected) |
CAGR |
Notes |
| 2025 |
$8.0 billion |
6.5% |
Steady growth driven by expanding nuclear medicine procedures |
| 2030 |
$11.0 billion |
6.5% |
Increased adoption in emerging markets, supply stabilizes |
Limitations and Risks
- Ongoing supply chain issues reduce accessible doses.
- Competition from PET tracers limits growth potential.
- Regulatory barriers in emerging markets can slow adoption.
- Technological advances may render some Tc-99m agents obsolete over the next decade.
Key Takeaways
- TECHNETIUM TC-99M MEBROFENIN remains a standard of care for renal imaging, with a mature market and established regulatory status.
- Clinical trials are minimal post-approval, focusing on protocol optimization rather than new indications.
- Market growth depends on supply chain stability, technological integration, and competition with PET tracers, which offer higher resolution imaging.
- The global market is projected to grow moderately, with expansion driven by emerging markets and technological improvements in imaging systems.
- Alternative radiopharmaceuticals and supply chain vulnerabilities represent significant risks to sustained demand.
FAQs
1. Is TECHNETIUM TC-99M MEBROFENIN expected to be replaced soon?
Not imminently. It remains widely used for renal imaging due to availability and proven efficacy. However, PET agents are gradually capturing market share.
2. Are there ongoing efforts to develop new radiopharmaceuticals for renal imaging?
Yes. Research focuses on PET tracers with higher resolution and newer agents with improved safety profiles, but these are not directly replacing Tc-99m agents immediately.
3. How do supply chain issues affect the market?
Molybdenum-99 shortages lead to limited Tc-99m availability, impacting clinical throughput and revenue for providers.
4. What regulatory changes could influence the market?
Approval of new imaging agents, streamlined pathways for generics or biosimilars, and supply chain reforms could reshape the market landscape.
5. What is the outlook for older Tc-99m agents versus newer imaging modalities?
Tc-99m agents will likely maintain niche roles for specific diagnostics due to cost and infrastructure, but the overall trend favors higher-resolution PET scans where available.
References
[1] MarketsandMarkets. (2022). Nuclear Medicine Market by Type, Application, and Region—Global Forecast to 2026.
